SciELO - Scientific Electronic Library Online

 
vol.35 issue1Prevalence of risk factors for metabolic syndrome and its components in community kitchen users in a district in Lima, PeruAnti-inflammatory effect of the flavonoid fraction of Lepechinia meyenii (Walp.) Epling (Sage) on leukocytes of patients with rheumatoid arthritis author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Peruana de Medicina Experimental y Salud Publica

Print version ISSN 1726-4634

Abstract

ALCARRAZ, Cindy et al. Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the peruvian national institute of neoplastic diseases. Rev. perú. med. exp. salud publica [online]. 2018, vol.35, n.1, pp.46-54. ISSN 1726-4634.  http://dx.doi.org/10.17843/rpmesp.2018.351.3598.

Objectives. To determine the rate of optimal cytoreduction in patients with advanced ovarian cancer who received neoadjuvant chemotherapy with dose-dense carboplatin and paclitaxel followed by interval debulking surgery (IDS). Materials and Methods. A retrospective study of a series of cases of Peruvian women treated with neoadjuvant chemotherapy with carboplatin (6 AUC mg/mL/min) and paclitaxel (80 mg/m2 weekly) followed by IDS, at the National Institute of Neoplastic Diseases during the 2010-2014 period. Results. The 41 patients who made it to the interval surgery had a median age of 59 years (range: 47-73 years). In 37 (90.2%) patients, high-grade serous adenocarcinoma histology was reported. Thirty-four (82.9%) achieved optimal cytoreduction and five (14.7%), a complete pathological response. Progression-free survival at one year and two years was 74.7% and 51.8%, respectively. Overall survival at one year and two years was 85.2% and 71.4%, respectively. The risk of progression and death was greater in patients without optimal cytoreduction and in patients with postsurgery levels of carcinoembryonic antigen 125 > 30 U/mL. Conclusions. Neoadjuvant therapy with dose-dense carboplatin and paclitaxel achieved an elevated frequency of optimal cytoreduction. The post-surgery levels of carcinoembryonic antigen 125 and optimal cytoreduction were independent factors of progression-free survival and overall survival.

Keywords : Ovarian neoplasms; Chemotherapy; Neoadjuvant therapy; Cytoreduction surgical procedures; Peru.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License